Anakinra Biosimilar Candidate

Paras Biopharmaceuticals has been intensively working on a Anakinra / IL1-RA biosimilar known as Kineret™) and has progressively achieved success. The company plans to mature good value within its Anakrina / IL1-RA asset and would like to highlight the following points / highlights to gauge your level of interest. Kineret™ (originator – Sobi) indicated for the treatment to 1) reduce the signs and symptoms and slow the damage of moderate to severe active rheumatoid arthritis (RA) in people aged 18 years and older, 2) treat people with a form of Cryopyrin-Associated Periodic Syndromes (CAPS) called Neonatal-Onset Multisystem Inflammatory Disease (NOMID) & 3) Treat people with Deficiency of Interleukin-1 Receptor Antagonist (DIRA) Paras Biopharmaceuticals have worked very extensively on Anakinra and have development, substantial data (unique program) Anakinra is "off patent" For further development and registration / approval, very limited further expenses are to made and hence the partnership. Furthermore, Paras Biopharmaceuticals seems to be the only company other than the innovator on such program. Paras Biopharmaceuticals looks to mature maximum value to the pool / joint sharing for further growth / return / rewards from the program. If you have an interest in the product and would like to know more, we would welcome the opportunity to set up a onsite meeting.